{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:30:44Z","timestamp":1792899044745,"version":"4.5.0"},"reference-count":16,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Mural Oncology","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,10,11]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating CD8<jats:sup>+<\/jats:sup> T cells and natural killer cells, with minimal expansion of regulatory T cells, thereby mitigating the risk of toxicities associated with high-affinity interleukin-2 receptor activation. Clinical outcomes with nemvaleukin are unknown. ARTISTRY-1 investigated the safety, recommended phase 2 dose (RP2D), and antitumor activity of nemvaleukin in patients with advanced solid tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a three-part, open-label, phase 1\/2 study: part A, dose-escalation monotherapy, part B, dose-expansion monotherapy, and part C, combination therapy with pembrolizumab. The study was conducted at 32 sites in 7 countries. Adult patients with advanced solid tumors were enrolled and received intravenous nemvaleukin once daily on days 1\u20135 (21-day cycle) at 0.1\u201310\u2009\u00b5g\/kg\/day (part A), or at the RP2D (part B), or with pembrolizumab (part C). Primary endpoints were RP2D selection and dose-limiting toxicities (part A), and overall response rate (ORR) and safety (parts B and C).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From July 2016 to March 2023, 243 patients were enrolled and treated (46, 74, and 166 in parts A, B, and C, respectively). The maximum tolerated dose was not reached. RP2D was determined as 6\u2009\u00b5g\/kg\/day. ORR with nemvaleukin monotherapy was 10% (7\/68; 95%\u2009CI 4 to 20), with seven partial responses (melanoma, n=4; renal cell carcinoma, n=3). Robust CD8<jats:sup>+<\/jats:sup> T and natural killer cell expansion, and minimal regulatory T cell expansion were observed following nemvaleukin treatment. ORR with nemvaleukin plus pembrolizumab was 13% (19\/144; 95%\u2009CI 8 to 20), with 5 complete and 14 partial responses; 6 responses were in PD-(L)1 inhibitor-approved and five in PD-(L)1 inhibitor-unapproved tumor types. Three responses were in patients with platinum-resistant ovarian cancer. The most common grade 3\u20134 treatment-related adverse events (TRAEs) in parts B and C, respectively, were neutropenia (49%, 21%) and anemia (10%, 11%); 4% of patients in each part discontinued due to TRAEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Nemvaleukin was well tolerated and demonstrated promising antitumor activity across heavily pretreated advanced solid tumors. Phase 2\/3 studies of nemvaleukin are ongoing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02799095\">NCT02799095<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-010143","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T11:45:13Z","timestamp":1732103113000},"page":"e010143","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02799095","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02799095","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04830124","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05092360","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-4571","authenticated-orcid":false,"given":"Ulka N","family":"Vaishampayan","sequence":"first","affiliation":[{"name":"Divison of Hematology\/Oncology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Muzaffar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Winer","sequence":"additional","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth D","family":"Rosen","sequence":"additional","affiliation":[{"name":"Hematology Oncology Association of the Treasure Coast, Port St. Lucie, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoper J","family":"Hoimes","sequence":"additional","affiliation":[{"name":"Phase I Program, Case Comprehensive Cancer Center, University Hospitals, Cleveland, Ohio, USA"},{"name":"Duke Cancer Institute, Duke University, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-3042","authenticated-orcid":false,"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl D","family":"Lewis","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora S","family":"Bruno","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dumas","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"McDermott","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Strauss","sequence":"additional","affiliation":[{"name":"Mary Crowley Cancer Research Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy S","family":"Chu","sequence":"additional","affiliation":[{"name":"University of Alberta\/Alberta Health Services, Cross Cancer Institute, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, The Gerald Bronfman Department of Oncology, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Summit Cancer Centers, Spokane, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-829X","authenticated-orcid":false,"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[{"name":"START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Dalal","sequence":"additional","affiliation":[{"name":"Mural Oncology, Inc, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Boni","sequence":"additional","affiliation":[{"name":"START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-7069","authenticated-orcid":false,"given":"Marc S","family":"Ernstoff","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment & Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsidhar","family":"Velcheti","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2025100301075464000_12.11.e010143.1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100301075464000_12.11.e010143.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.004"},{"key":"2025100301075464000_12.11.e010143.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.018"},{"key":"2025100301075464000_12.11.e010143.4","doi-asserted-by":"crossref","first-page":"1-11","DOI":"10.1155\/2021\/7855808","article-title":"Interleukin 2-based fusion proteins for the treatment of cancer","volume":"2021","author":"MacDonald","year":"2021","journal-title":"J Immunol Res"},{"key":"2025100301075464000_12.11.e010143.5","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100301075464000_12.11.e010143.6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46266"},{"key":"2025100301075464000_12.11.e010143.7","first-page":"79","article-title":"Update on use of aldesleukin for treatment of high-risk metastatic melanoma","volume":"4","author":"Amaria","year":"2015","journal-title":"Immunotargets Ther"},{"key":"2025100301075464000_12.11.e010143.8","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2025100301075464000_12.11.e010143.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000673","article-title":"ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy","volume":"8","author":"Lopes","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100301075464000_12.11.e010143.10","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.121.000612"},{"key":"2025100301075464000_12.11.e010143.11","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-591"},{"key":"2025100301075464000_12.11.e010143.12","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2025100301075464000_12.11.e010143.13","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2147\/DDDT.S146286","article-title":"Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2025100301075464000_12.11.e010143.14","doi-asserted-by":"crossref","first-page":"113530","DOI":"10.1016\/j.ejca.2024.113530","article-title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","volume":"199","author":"Brahmer","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025100301075464000_12.11.e010143.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306"},{"key":"2025100301075464000_12.11.e010143.16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126532","article-title":"Ovarian cancer immunotherapy and personalized medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:08:06Z","timestamp":1759478886000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,20]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/jitc-2024-010143"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010143","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}